In line with the recent work of Drew and collaborators [12], the present work used a pool of 107 CKD patients to ascertain the potential use of plasmatic Klotho, FGF23 or both, as markers for CKD-associated cardiac disease and to discuss their eventual use as therapeutic targets in CKD. Here, FGF23 is linked to chronic kidney disease.